- Home
- CELU vs PULM Comparison
CELU vs PULM Comparison
Compare CELU & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELU
- PULM
- Stock Information
- Founded
- CELU 2016
- PULM 2003
- Country
- CELU United States
- PULM United States
- Employees
- CELU N/A
- PULM 2
- Industry
- CELU Biotechnology: Pharmaceutical Preparations
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- CELU Health Care
- PULM Health Care
- Exchange
- CELU Nasdaq
- PULM Nasdaq
- Market Cap
- CELU 37.7M
- PULM 28.3M
- IPO Year
- CELU N/A
- PULM N/A
- Fundamental
- Price
- CELU $2.11
- PULM $8.98
- Analyst Decision
- CELU
- PULM
- Analyst Count
- CELU 0
- PULM 0
- Target Price
- CELU N/A
- PULM N/A
- AVG Volume (30 Days)
- CELU 91.2K
- PULM 20.6K
- Earning Date
- CELU 05-08-2025
- PULM 05-15-2025
- Dividend Yield
- CELU N/A
- PULM N/A
- EPS Growth
- CELU N/A
- PULM N/A
- EPS
- CELU N/A
- PULM N/A
- Revenue
- CELU $54,220,000.00
- PULM $1,921,000.00
- Revenue This Year
- CELU $23.29
- PULM N/A
- Revenue Next Year
- CELU N/A
- PULM $134.88
- P/E Ratio
- CELU N/A
- PULM N/A
- Revenue Growth
- CELU 138.11
- PULM N/A
- 52 Week Low
- CELU $1.00
- PULM $1.78
- 52 Week High
- CELU $5.22
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- CELU 54.10
- PULM 69.60
- Support Level
- CELU $1.90
- PULM $7.94
- Resistance Level
- CELU $2.47
- PULM $9.37
- Average True Range (ATR)
- CELU 0.29
- PULM 0.67
- MACD
- CELU 0.01
- PULM 0.29
- Stochastic Oscillator
- CELU 58.25
- PULM 88.51
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).